Cytokinetics (NASDAQ: CYTK)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Cytokinetics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cytokinetics Company Info
Cytokinetics is a biopharmaceutical company focused on developing small-molecule therapeutics for the treatment of cardiovascular diseases and cancer.
News & Analysis
The company's new heart drug candidate produced encouraging clinical trial results.
The Food and Drug Administration is fast-tracking the biotech's lead drug candidate.
News of a public debt offering didn't go over well with investors.
The clinical-stage biotech's long-running partnership with Amgen took another big step forward.
The biotech will join the S&P SmallCap 600 index.
What the biotech didn't say might have caused its downfall.
Cytokinetics Inc. shares jumped by over 10% earlier in the day after reporting financial results for 2015.
Shares of the clinical-stage biopharma Cytokinetics roared higher today. Here's why.
Valuation
Earnings Transcripts
CYTK earnings call for the period ending September 30, 2021.
CYTK earnings call for the period ending June 30, 2021.
CYTK earnings call for the period ending March 31, 2021.
CYTK earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.